TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2805024
Drug: Cisapride, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 0.1 to 0.2 mg/kg three times daily for up to four weeks
Study: 21595543
Drug: Traditional Japanese
Normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Japanese massage therapy (40‐minute full-body massage)
Study: 20705788
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (IV dexmedetomidine 2 μg · kg(‐1) over 10 minutes, followed by 0.7 μg · kg(‐1) · h(‐1))
Study: 20705788
Drug: Fentanyl bolus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl bolus (IV fentanyl 1 μg · kg(‐1))
Study: 15847998
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam freeze-dried tablet (Proxalyoc, Cephalon)
Study: 15847998
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam capsule (Feldene, Pfizer)
Study: 10914864
Drug: Calcitriol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.5 microg) and 1200 mg calcium daily
Study: 8985030
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course radiotherapy (20 Gy in 1 week, daily dose 4 Gy)
Study: 8985030
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (30 Gy in 3 weeks, daily dose 2 Gy)
Study: 1569224
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine digluconate (CHX) used in oral irrigator, 2 x daily for 56 days
Study: 1569224
Drug: Placebo used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo used in oral irrigator
Study: 236108
Drug: Flurazepam, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurazepam, 30 mg
Study: 21543662
Drug: Atomoxetine (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (10, 40, 90, or 120 mg single dose; 40 or 60 mg twice a day for 7 days)
Study: 21125038
Drug: Revascularisation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularisation plus medical therapy
Study: 15696181
Drug: Pilocarpine hydrochloride
Normalized name: Pilocarpine Hydrochloride
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine hydrochloride 5 mg tablet
Study: 17115983
Drug: Topiramate 200
Normalized name: topiramate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 200 mg/day
Study: 9201655
Drug: Intravenous gammaglobulin
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gammaglobulin (1 gm/kg, max 1 litre of 6 gm/100 ml in 10% w/v maltose solution)
Study: 9201655
Drug: Dummy solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy solution (10% w/v maltose solution with 1% albumin of equivalent volume)
Study: 1332529
Drug: S(+)‐ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine (1 mg/kg BW)
Study: 15886286
Drug: Nitroglycerin (NIT)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NIT) at a starting dose of 10 microg/min
Study: 15886286
Drug: Nitroprusside (NIP)
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nitroprusside (NIP) at a starting dose of 0.25 microg/kg/min
Study: 11840436
Drug: COBRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA therapy (combination of prednisolone, methotrexate, and sulfasalazine)
Study: 15146408
Drug: SSZ monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSZ monotherapy
Study: 15338488
Drug: COBRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA therapy
Study: 29083444
Drug: Development of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development of P4 Systems medicine inspired new methodologies in predictive maintenance
Study: 23636283
Drug: Sodium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium intake > 1200 mg/day
Study: 19689798
Drug: Reference linoleic
Normalized name: linoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference linoleic acid oil preparation
Study: 17239165
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clopidogrel loading dose + 325 mg ASA
Study: 17239165
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clopidogrel loading dose + 325 mg ASA
Study: 11521985
Drug: L-NAME 180
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME 180 microg/kg/h
Study: 11521985
Drug: Intraduodenal lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal lipid infusion (2 kcal/min)
Study: 9972119
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg doxycycline BID (Periostat)
Study: 3290018
Drug: sorbinil (aldose
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorbinil (aldose reductase inhibitor)
Study: 18253118
Drug: Irinotecan 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 60 mg m(‐2) on days 1 and 8 and cisplatin 60 mg m(‐2) on day 1 with etoposide 50 mg m(‐2) on days 1‐3 (n=55)
Study: 18253118
Drug: Irinotecan 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 60 mg m(‐2) on days 1 and 8 and cisplatin 60 mg m(‐2) on day 1 without etoposide (n=54)
Study: 10477777
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of enoxaparin
Study: 10477777
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of enoxaparin
Study: 1467096
Drug: i.m. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. morphine 0.15 mg kg‐1 as required
Study: 1467096
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with i.v. morphine 1 mg and a 5-min lock out time
Study: 20053951
Drug: EMG‐BFB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG‐BFB treatment
Study: 9665239
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional therapy)
Study: 18725513
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day of conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone acetate
Study: 12645831
Drug: Sequential i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential i.v. ceftriaxone/oral cefuroxime
Study: 8879372
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg twice a day
Study: 28592620
Drug: Trebananib 10
Normalized name: Trebananib
DrugBank: Trebananib (DB12056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib 10 mg/kg plus sorafenib 400 mg orally twice daily
Study: 28592620
Drug: Trebananib 15
Normalized name: Trebananib
DrugBank: Trebananib (DB12056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib 15 mg/kg plus sorafenib 400 mg orally twice daily
Study: 8181192
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg daily for 1 week)
Study: 23331498
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg)
Study: 18355218
Drug: Home visiting
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visiting (treatment as usual)
Study: 16931678
Drug: Valdecoxib 20
Normalized name: valdecoxib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 20 mg every 12 h for 72 h postoperatively
Study: 12788192
Drug: Pilocarpine 5
Normalized name: PILOCARPINE 5MG/UNT OPH,CRC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine 5 mg
Study: 17426226
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol
Study: 11119400
Drug: Routine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotic treatment
Study: 11119400
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of patient and physician education
Study: 2885853
Drug: Astemizole suspension
Normalized name: Astemizole
DrugBank: Astemizole (DB00637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Astemizole suspension (5 ml, 1 mg/ml) once daily
Study: 2885853
Drug: Terfenadine suspension
Normalized name: terfenadine Oral Suspension
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine suspension (5 ml, 6 mg/ml) twice daily
Study: 23410501
Drug: Back massage
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back massage therapy (20 minutes session for 5 consecutive days)
Study: 22236804
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n = 16)
Study: 30779100
Drug: Oral diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diet (OD)
Study: 11073745
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (3 mg/kg/d)
Study: 1312797
Drug: Mexiletine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (750 mg/day)
Study: 2996726
Drug: Pindolol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5-10 mg twice a day)
Study: 2996726
Drug: Propranolol (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40-80 mg 4 times a day)
Study: 31343376
Drug: DMSO‐L (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO‐L (local administration)
Study: 31343376
Drug: DMSO‐IP (intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO‐IP (intraperitoneal administration)
Study: 31279564
Drug: MenACWY-CRM (booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM (booster dose)
Study: 25744224
Drug: MenACWY-CRM (primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM (primary dose)
Study: 21512577
Drug: Two double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two double doses of influenza vaccine over 28 days
Study: 21512577
Drug: Single standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single standard dose of influenza vaccine
Study: 14872039
Drug: Phenobarbitone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (40 mg/kg as first line)
Study: 10714475
Drug: 5-day moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day moxifloxacin 400 mg once daily
Study: 9324147
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid (IVF), n = 17
Study: 2412521
Drug: Monoamine oxidase
Normalized name: Monoamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine oxidase inhibitor (N=9)
Study: 25158287
Drug: Caffeinated energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated energy drink (3 mg caffeine per kg body mass)
Study: 21600090
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose chemotherapy plus valproic acid (VPA)
Study: 21600090
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose chemotherapy regimen
Study: 18329827
Drug: Medication clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication clinic only
Study: 18329827
Drug: Medication clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication clinic plus BRENDA
Study: 18329827
Drug: Medication clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication clinic plus cognitive behavioral therapy (CBT)
Study: 10934074
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI)
Study: 12511312
Drug: High-dose albuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose albuterol (15 mg/hr)
Study: 12511312
Drug: Usual-dose albuterol
Normalized name: albuterol Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-dose albuterol (7.5 mg/hr)
Study: 10371571
Drug: Subcutaneous interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interleukin-2 (3 million IU/m2 twice daily for 5 days)
Study: 1650528
Drug: adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant chemotherapy (CAV) plus intrapleural BCG
Study: 6868628
Drug: Percutaneous high‐voltage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous high‐voltage therapy with cobalt 60 (51 patients)
Study: 26388169
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg oxantel pamoate
Study: 30745388
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg oxantel pamoate
Study: 22590991
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron and 250 µg folate with or without 15 mg zinc
Study: 11902732
Drug: IFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN plus Ara‐C (5 million units/m2 IFN once per day and 20 mg/m2 Ara‐C for 10 days each month)
Study: 2151889
Drug: Enoximone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.5 mg/kg)
Study: 19017758
Drug: Detemir once
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Detemir once daily and aspart before meals (n = 67)
Study: 17523932
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during 4 weeks of TL01 therapy
Study: 17523932
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite 400 microg daily
Study: 6653683
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (SRT)
Study: 2455107
Drug: Felodipine 2.5
Normalized name: felodipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 2.5 mg b.i.d.
Study: 2455107
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg b.i.d.
Study: 2455107
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg b.i.d.
Study: 6202963
Drug: Felodipine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (all doses)
Study: 12972722
Drug: no interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: no interval treatment for 12 weeks followed by semi-standardized acupuncture (75 patients, waiting list control)
Study: 8769387
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sandostatin LAR (20 mg and 30 mg doses at 4-week intervals)
Study: 1413981
Drug: Diuretic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic and possibly a beta-blocker or reserpine (active treatment group)
Study: 31331587
Drug: Methylsulfonylmethane (MSM)
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylsulfonylmethane (MSM) 6g daily
Study: 23546629
Drug: Bufei Yishen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufei Yishen Granule combined with Shufei Tie acupoint sticking therapy
Study: 20884928
Drug: Mucoadhesive disks
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mucoadhesive disks (OraMoist) applied three times daily
Study: 20884928
Drug: Placebo mucoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mucoadhesive disks applied three times daily
Study: 15669885
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 to 150 mg/day
Study: 17413099
Drug: Lower-protein (LP)
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-protein (LP) group; 0.9 g protein . kg(‐1) . d(‐1)
Study: 15492337
Drug: Ciprofloxacin, 500
Normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 500 mg twice daily
Study: 11444447
Drug: Epidural normal
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural normal saline followed by iv 2% lidocaine (0.05 mL.kg(‐1)) then propofol
Study: 321183
Drug: sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulindac 200 mg twice daily
Study: 17297383
Drug: Rifalazil 25
Normalized name: Rifalazil
DrugBank: Rifalazil (DB04934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifalazil 25 mg
Study: 17297383
Drug: Azithromycin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1.0 g
Study: 15385119
Drug: 0.3 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/m2 daily for 5 days every 3 weeks (Arm A)
Study: 15385119
Drug: 2.1 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.1 mg/m2 weekly for 3 weeks out of 4 (Arm B)
Study: 8005182
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg tds)
Study: 31863406
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy plus migraine education (ACT-ED)
Study: 29092982
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus of 20 mg/kg IV TXA before incision (group A)
Study: 29092982
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus followed by a second bolus of 1 g IV TXA three hours later (group B)
Study: 29092982
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus followed by two boluses of 1 g IV TXA three and six hours later (group C)
Study: 23200803
Drug: Cardioselective β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioselective β blockers
Study: 18381090
Drug: Support for
Normalized name: GNP Diabetic Support Formula Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support for clinical trials and drug development
Study: 12761013
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 mL normal saline)
Study: 11061604
Drug: Cisplatin-etoposide-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-etoposide-based chemotherapy
Study: 31219248
Drug: Ertugliflozin/Sitagliptin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin/Sitagliptin FDC tablet (5 mg/50 mg)
Study: 31219248
Drug: Ertugliflozin/Sitagliptin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin/Sitagliptin FDC tablet (5 mg/100 mg)
Study: 31219248
Drug: Ertugliflozin/Sitagliptin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin/Sitagliptin FDC tablet (15 mg/50 mg)
Study: 31219248
Drug: Ertugliflozin/Sitagliptin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin/Sitagliptin FDC tablet (15 mg/100 mg)
Study: 28543263
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g mesalazine once daily (SAG-51)
Study: 28543263
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g mesalazine once daily (SAG-51)
Study: 21114549
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg karaya saponin
Study: 21114549
Drug: 75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/kg karaya saponin
Study: 18165565
Drug: Ketamine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.75 mg/kg
Study: 7888516
Drug: Meperidine 25
Normalized name: meperidine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 25 mg
Study: 14673011
Drug: methylphenidate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate (0.5 mg/kg, i.v.)
Study: 8412414
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg d-fenfluramine
Study: 8412414
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg l-fenfluramine
Study: 23298079
Drug: Hydrogel injection
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel injection
Study: 12802837
Drug: Self-administered medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered medication program
Study: 12802837
Drug: Nurse-administered medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered medications
Study: 12378376
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for hypertension in macroalbuminuric patients
Study: 12378376
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of more than one anti-hypertensive drug
Study: 16858168
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of ACE inhibitors
Study: 28353056
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg oral psilocybin
Study: 28353056
Drug: 0.45 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/kg oral psilocybin
Study: 28353056
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg oral psilocybin
Study: 23407049
Drug: First-line monotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line monotherapy capecitabine
Study: 23407049
Drug: Capecitabine-irinotecan combination
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine-irinotecan combination therapy
Study: 16735941
Drug: EA 1.8
Normalized name: Anti-Nausea 1.87g-1.87g-21.5mg/5mL Liquid (Cherry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA 1.8 mg/day
Study: 16735941
Drug: EA 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA 0.9 mg/day
Study: 16735941
Drug: EA 0.45
Normalized name: urea 0.45 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA 0.45 mg/day
Study: 16735941
Drug: EA 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA 0.9 mg/day and EA 1.8 mg/day
Study: 31942927
Drug: Control (placebo)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (placebo) treatment